CG Oncology, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
CG Oncology, Inc. (CGON) reported Increase (Decrease) in Prepaid Expense and Other Assets of $4.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- CG Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$3.18M.
- CG Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $8.07M, a 1377.29% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $1.81M, a 114.96% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $324.00K, a 31.93% decline year-over-year.
- CG Oncology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.90M, a 67.03% decline from fiscal 2024.
- CG Oncology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $5.76M, a 111.60% increase from fiscal 2023.
- CG Oncology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.72M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.88M 10-Q · filed 2026-08-06 | $6.69M derived: sum of 3 quarters · filed 2026-08-06 | $7.02M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $8.07M 10-Q · filed 2026-05-08 | $9.88M derived: sum of 2 quarters · filed 2026-05-08 | $10.20M derived: sum of 3 quarters · filed 2026-05-08 | $9.42M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.13M derived: sum of 2 quarters · filed 2026-02-27 | $1.35M derived: sum of 3 quarters · filed 2026-08-06 | $1.90M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $324.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$456.00K derived: sum of 2 quarters · filed 2026-08-06 | $90.00K 10-Q · filed 2025-11-14 | $932.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$780.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$234.00K 10-Q · filed 2026-08-06 | -$15.00K 10-Q · filed 2025-08-08 | $608.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.08M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $546.00K 10-Q · filed 2026-05-08 | $982.00K 10-Q · filed 2025-05-13 | $1.39M derived: sum of 2 quarters · filed 2026-05-08 | $1.86M derived: sum of 3 quarters · filed 2026-05-08 | $654.00K derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $842.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.32M derived: sum of 2 quarters · filed 2026-02-27 | $108.00K derived: sum of 3 quarters · filed 2026-02-27 | $5.76M 10-K · filed 2026-02-27 | $5.07M 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$734.00K derived: sum of 2 quarters · filed 2025-11-14 | $4.92M 10-Q · filed 2025-11-14 | $4.88M 10-Q · filed 2024-11-12 | $5.47M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2024-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $4.44M 10-Q · filed 2025-08-08 | $5.00M derived: sum of 3 quarters · filed 2026-02-27 | $6.86M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $5.65M 10-Q · filed 2025-05-13 | $6.21M derived: sum of 2 quarters · filed 2026-02-27 | $8.07M derived: sum of 3 quarters · filed 2026-02-27 | $8.60M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $555.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $2.42M derived: sum of 2 quarters · filed 2026-02-27 | $2.95M derived: sum of 3 quarters · filed 2026-02-27 | $2.72M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.39M derived: sum of 2 quarters · filed 2024-11-12 | $2.17M 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | $531.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $307.00K 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | -$224.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |